Restricted accessResearch articleFirst published online 2019-06
Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression
Identifying tissue sources of HIV that rebound following “failure” of antiretroviral therapy (ART) is critical to evaluating cure strategies. To assess the role of the uterine cervix and peripheral blood mononuclear cells (PBMC) as viral reservoirs, nearest-neighbor phylogenetic analyses compared genetic relatedness of tissue sequences during ART suppression to those detected in plasma at viral rebound. Blood and genital tract specimens from a natural history cohort of HIV-infected women were collected over 5 years. HIV DNA sequences extracted from PBMC and cervical biopsies during ART suppression and plasma RNA from rebound (defined as HIV RNA >3 log10 copies/mL) were derived by single-genome amplification. Phylogenetic and nearest-neighbor analyses of HIV env sequences and drug resistance in pol sequences were compared between tissues. Nine instances of plasma viral rebound (median HIV RNA 3.6 log10 c/mL; IQR: 3.1–3.8) were detected in 7 of 57 women. Nearest-neighbor analyses found rebound plasma sequences were closer to uterine cervical sequences in 4/9 (44%), closer to PBMC in 3/9 (33%), and ambiguous in 2/9 (22%) cases. Rebound plasma clades (n = 27) shared identical sequences in seven instances with the cervix versus two with PBMC. Novel drug resistance mutations were detected in 4/9 (44%) rebounds. The observed tendency for greater sharing of identical HIV variants and greater nearest-neighbor association between rebounding plasma and uterine cervical versus PBMC sequences suggests that the uterine cervix may be a relevant HIV reservoir. The cervix, a readily accessible tissue in women that can be repeatedly sampled, could help assess the HIV reservoir when evaluating cure strategies.
Get full access to this article
View all access options for this article.
References
1.
FinziD, HermankovaM, PiersonT, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997; 278:1295–1300.
2.
ChomontN, El-FarM, AncutaP, et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med, 2009; 15:893–900.
3.
OrtizGM, WellonsM, BrancatoJ, et al.: Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A, 2001; 98:13288–13293.
4.
DybulM, DaucherM, JensenMA, et al.: Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy. J Virol Mar, 2003; 77:3229–3237.
5.
FischerM, HafnerR, SchneiderC, et al.: HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS, 2003; 17:195–199.
6.
FischerM, JoosB, HirschelB, et al.: Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. J Infect Dis, 2004; 190:1979–1988.
7.
PapasavvasE, KostmanJR, ThielB, et al.: HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol, 2006; 26:40–54.
8.
JoosB, FischerM, KusterH, et al.: HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A, 2008; 105:16725–16730.
9.
CastroP, PlanaM, GonzalezR, et al.: Influence of episodes of intermittent viremia (“blips”) on immune responses and viral load rebound in successfully treated HIV-infected patients. AIDS Res Hum Retrovir, 2013; 29:68–76.
10.
FidlerS, OlsonA, FoxJ, et al.: The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. J Intl AIDS Soc, 2014; 17(4Suppl 3):19820.
11.
SimonettiFR, SobolewskiMD, FyneE, et al.: Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proc Natl Acad Sci U S A, 2016; 113:1883–1888.
12.
ChunT-W, CarruthL, FinziD, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1997; 387:183–188.
ChunTW, EngelD, BerreyMM, SheaT, CoreyL, FauciAS: Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A, 1998; 95:8869–8873.
15.
ImamichiH, CrandallKA, NatarajanV, et al.: Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis, 2001; 183:36–50.
16.
HoriikeM, IwamiS, KodamaM, et al.: Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology, 2012; 423:107–118.
17.
WoodlandDL, KohlmeierJE: Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol, 2009; 9:153–161.
18.
MasopustD, SchenkelJM. The integration of T cell migration, differentiation and function. Nat Rev Immunol, 2013; 13:309–320.
19.
FarberDL, YudaninNA, RestifoNP: Human memory T cells: Generation, compartmentalization and homeostasis. Nat Rev Immunol, 2014; 14:24–35.
20.
LernerP, GuadalupeM, DonovanR, et al.: The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol, 2011; 85:4772–4782.
21.
KearneyMF, SpindlerJ, ShaoW, et al.: Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog, 2014; 10:e1004010.
22.
KearneyMF, WiegandA, ShaoW, et al.: Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy. J Virol, 2015; 90:1369–1376.
23.
RothenbergerMK, MutuluuzaCK, SsaliF, et al.: Inguinal lymph node and anorectal mucosal biopsies for human immunodeficiency virus research protocols in an emerging nation: Patient outcomes and lessons learned. Surg Infect (Larchmt), 2015; 16:68–71.
24.
RothenbergerMK, KeeleBF, WietgrefeSW, et al.: Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci U S A, 2015; 112:E1126–E1134.
25.
MatsumuraJ, ShimizuM, OmiK, et al.: A possible origin of emerged HIV-1 after interrupting anti-retroviral therapy. Biomed Res, 2014; 35:1–8.
26.
BullME, LearnGH, McElhoneS, et al.: Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol, 2009; 83:6020–6028.
27.
BullME, HeathLM, McKernan-MullinJL, et al.Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time. J Infect Dis, 2013; 207:1206–1215.
28.
TobinNH, LearnGH, HolteSE, et al.Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus. J Virol, 2005; 79:9625–9634.
29.
GuindonS, LethiecF, DurouxP, GascuelO: PHYML Online—a web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res, 2005; 33(Web Server issue):W557–W559.
30.
DengW, MaustBS, NickleDC, et al.: DIVEIN: A web server to analyze phylogenies, sequence divergence, diversity, and informative sites. Biotechniques, 2010; 48:405–408.
31.
ShankarappaR, MargolickJB, GangeSJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol, 1999; 73:10489–10502.
32.
GilbertPB, RossiniAJ, ShankarappaR: Two-sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics, 2005; 61:106–117.
33.
SlatkinM, MaddisonWP: A cladistic measure of gene flow inferred from the phylogenies of alleles. Genetics, 1989; 123:603–613.
34.
HudsonRR: A new statistic for detecting genetic differentiation. Genetics, 2000; 155:2011–2014.
35.
ZarateS, PondSL, ShapshakP, FrostSD: Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol, 2007; 81:6643–6651.
GiorgiEE, BhattacharyaT: A note on two-sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics, 2012; 68:1323–1326; author reply 1326.
38.
SahuGK, PaarD, FrostSD, SmithMM, WeaverS, CloydMW: Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol, 2009; 81:9–15.
39.
SharkeyM, BabicDZ, GreenoughT, GulickR, KuritzkesDR, StevensonM: Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog, 2011; 7:e1001303.
40.
FletcherCV, StaskusK, WietgrefeSW, et al.: Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A, 2014; 111:2307–2312.
41.
MullinsJI, FrenkelLM: Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy. J Infect Dis, 2017; 215(Suppl_3):S119–S127.
42.
BaileyJR, SedaghatAR, KiefferT, et al.: Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol, 2006; 80:6441–6457.
43.
BrennanTP, WoodsJO, SedaghatAR, SilicianoJD, SilicianoRF, WilkeCO: Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol, 2009; 83:8470–8481.
44.
MavignerM, DelobelP, CazabatM, et al.: HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One, 2009; 4:e7658.
45.
Martinez-PicadoJ, FrostSD, IzquierdoN, et al.: Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J Virol, 2002; 76:12344–12348.
46.
CilloAR, VagratianD, BedisonMA, et al.Improved Single-Copy Assays for Quantification of Persistent HIV-1 Viremia in Patients on Suppressive Antiretroviral Therapy. J Clin Microbiol Nov, 2014; 52:3944–3951.
47.
BullME, MitchellC, SoriaJ, et al.: Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation. AIDS, 2018; 32:1389–1401.
48.
ConnorRI, SheridanKE, CeradiniD, ChoeS, LandauNR: Change in coreceptor use correlates with disease progression in HIV-1—infected individuals. J Exp Med, 1997; 185:621–628.
49.
BrummeZL, GoodrichJ, MayerHB, et al.: Molecular and Clinical Epidemiology of CXCR4-Using HIV-1 in a Large Population of Antiretroviral-Naive Individuals. J Infect Dis, 2005; 192:466–474.
50.
BaderJ, DaumerM, Schoni-AffolterF, et al.: Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1. Clin Infect Dis, 2017; 64:295–300.
51.
BleulCC, WuL, HoxieJA, SpringerTA, MackayCR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A, 1997; 94:1925–1930.
52.
DelobelP, NugeyreMT, CazabatM, et al.: Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol, 2006; 80:10229–10236.
53.
LopezCA, VazquezM, HillMD, et al.: Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART. Arch Virol, 2010; 155:895–903.
54.
TorresB, GuardoAC, LealL, et al.: Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. J Intl AIDS Soc, 2014; 17:19246.
55.
VicenziE, LioP, PoliG: The puzzling role of CXCR4 in human immunodeficiency virus infection. Theranostics, 2013; 3:18–25.
56.
SivroA, LajoieJ, KimaniJ, et al.: Age and menopause affect the expression of specific cytokines/chemokines in plasma and cervical lavage samples from female sex workers in Nairobi, Kenya. Immun Ageing, 2013; 10:42.
57.
WaclecheVS, GouletJP, GosselinA, et al.: New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology, 2016; 13:59.
58.
Hey-NguyenWJ, XuY, PearsonCF, et al.: Quantification of residual germinal center activity and HIV-1 DNA and RNA levels using fine needle biopsies of lymph nodes during antiretroviral therapy. AIDS Res Hum Retrovir, 2017; 33:648–657.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
